[1]杨建安 王斌 秦自科 李靖.晚期前列腺癌患者行间歇性内分泌治疗的疗效分析[J].中华腔镜泌尿外科杂志(电子版),2014,(01):49-53.
　Yang Jianan*,Wang Bin,Qin Zike,et al.The intermittent hormonal therapy for the patients with advanced prostate cancer[J].,2014,(01):49-53.
点击复制

晚期前列腺癌患者行间歇性内分泌治疗的疗效分析()
分享到：

中华腔镜泌尿外科杂志(电子版)[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2014年01期
页码:
49-53
栏目:
临床研究
出版日期:
2014-02-25

文章信息/Info

Title:
The intermittent hormonal therapy for the patients with advanced prostate cancer
作者:
杨建安 王斌 秦自科 李靖
510095广州，广州医科大学附属肿瘤医院泌尿肿瘤外科（杨建安、王斌、李靖）； 510060广州，中山大学附属肿瘤医院泌尿外科（秦自科）
Author(s):
Yang Jian′an*;  Wang Bin;  Qin Zike;  Li Jing.
Department of Urology, the Tumor Hospital Affiliated to Guangzhou medical college, Guangzhou 510095, China
关键词:
前列腺癌; 内分泌治疗; 疗效
摘要:
目的 探讨间歇性内分泌治疗在晚期前列腺癌患者中的疗效，并分析影响疗效的相关因素。方法 2004年 9月到 2012年 7月间收治晚期前列腺癌患者首先进行 6～9个月的内分泌治疗，然后进行疗效评估，将对内分泌治疗敏感的患者随机分为间歇治疗组和持续治疗组，观察两组的疗效、毒副作用及患者的生活质量评分等指标，并分析间歇治疗组中影响患者预后的相关因素。结果 共收治 174例晚期前列腺癌患者，有 130例患者对内分泌治疗敏感，其中 58例患者接受间歇性内分泌治疗， 72例患者接受持续性内分泌治疗。间歇治疗组患者的生活质量 KPS评分明显高于持续治疗组（80 vs 70, P＜0.05），相关并发症发生率也低于持续治疗组。但两组患者的 5年内发展成为非激素依赖性前列腺癌的比例（ 37% vs 41%）及患者的 5年生存率（ 72% vs 63%）无明显差异。Cox多因素分析显示晚期前列腺癌患者的 Gleason评分及第一次治疗后 PSA水平与患者的预后密切相关，可作为判断能否行间歇性内分泌治疗及预后的重要指标。结论 对于晚期前列腺癌患者行间歇性内分泌治疗安全可行、疗效确切，对患者的生活质量影响小，同时也可减少患者的经济压力。

参考文献/References:

[1] McLeod DG. Hormonal therapy: historical perspective to future directions[J]. Urology, 2003, 61(2 suppl 1): 3-7.
[2] Bruchovsky N, Rennie PS, Coldman AJ, et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma[J]. Cancer Res, 1990, 50(8): 2275-2282.
[3] Akakura K, Bruchovsky N, Goldenberg SL, et al. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen[J]. Cancer, 1993, 71 (9): 2782-2790.
[4] Higano C . Androgen deprivation therapy : monitoring and managing the complications[J]. Hematol Oncol Clin North Am, 2006, 20(4): 909-923.
[5] Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists[J]. J Clin Endocrinol Metab, 2001, 86(6): 2787-2791.
[6] Higano C, Shields A, Wood N, et al. Bone mineral density in patients with prostate cancer without bone metastases treated with intermittent androgen suppression [J ]. Urology, 2004 , 64 (6):1182-1186.
[7] Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model [J]. J Steroid Biochem Mol Biol, 1996, 58 (2):139-146.
[8] Eggener SE , Stern JA, Jain PM, et al . Enhancement of intermittent androgen ablation by “off-cycle”maintenance with finasteride in LNCaP prostate cancer xenograft model[J]. Prostate,2006, 66(5): 495-502.
[9] Calais da Silva FE, Bono AV, Whelan P, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group [ J ] . Eur Urol , 2009 , 55 ( 6 ) :1269-1277.
[10] Shaw GL, Wilson P, Cuzick J, et al. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients[J]. BJU Int,2007, 99(5): 1056-1065.
[11] Mottet N, Van Damme J, Loulidi S, et al. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial[J]. BJU Int, 2012, 110(9): 1262-1269.
[12] Salonen AJ, Viitanen J, Lundstedt S, et al. Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation [J]. J Urol, 2008, 180(3): 915-919.
[13] Hussain M, Tangen CM, Higano C, et al. Absolute prostate -specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)[J]. J Clin Oncol, 2006, 24(24): 3984-3990.
[14] Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer[J]. Eur Urol, 2008, 53(1): 68-80.
[15] Gleave M, Klotz L, Taneja SS. The continued debate: intermittent vs. continuous hormonal ablation for metastatic prostate cancer[J].Urol Oncol, 2009, 27(1): 81-86.
[16] Shaw G, Oliver RT. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer[J]. Surg Oncol, 2009, 18(3): 275-282.

相似文献/References:

[1]周建华,高新,蔡育彬,等.腹腔镜前列腺癌根治术126例3年随访结果[J].中华腔镜泌尿外科杂志(电子版),2007,(01):22.
　ZHOU Jian-hua,GAO Xin,CAI Yu-bin,et al.Results of study of 126 cases underwent laparoscopic radical Prostatectomy during three years' follow-up[J].,2007,(01):22.
[2]关健强,周少丽,龚楚链,等.腹腔镜下前列腺癌根治术中呼气末CO2分压的变化及意义[J].中华腔镜泌尿外科杂志(电子版),2008,(03):37.
　GUAN Jian-qiang,ZHOU Shao-li,GONG Chu-lian,et al.Difference between arterial and end-tidal carbon dioxide pressures in laparoscopic radical prostarectome[J].,2008,(01):37.
[3]乔鹏,邢念增.经腹膜外腹腔镜前列腺癌根治术(附9例报告)[J].中华腔镜泌尿外科杂志(电子版),2009,(01):25.
　QIAO Peng,XING Nian-zeng.Extraperitoneal laparoscopic radical prostatectomy: a report of 9 cases[J].,2009,(01):25.
[4]进展,孙其鹏,高新.TMPRSS2-ETS融合基因在前列腺癌研究的进展[J].中华腔镜泌尿外科杂志(电子版),2009,(04):354.
[5]黄海,杜涛,黄健,等.高效抑制核因子κ-B的茎环RNA基因序列的获得[J].中华腔镜泌尿外科杂志(电子版),2009,(05):444.
[6]高新,邱剑光,周祥福,等.腹腔镜前列腺癌根治术5年随访结果——中国单中心170例报道[J].中华腔镜泌尿外科杂志(电子版),2010,(01):2.
　GAO Xin,QIU Jian-guang,ZHOU Xiang-fu,et al.Laparoscopic radical prostatectomy:oncological and functional results of 170 patients with a minimum 5-year follow-up[J].,2010,(01):2.
[7]刘伟鹏,庞俊,李辽源,等.前列腺癌CRMP4基因启动子甲基化研究[J].中华腔镜泌尿外科杂志(电子版),2010,(01):57.
　LIU Wei-peng,PANG Jun,LI Liao-yuan,et al.A study on promoter methylation of CRMP4 in prostate cancer[J].,2010,(01):57.
[8]孙其鹏,庞俊,李辽源,等.荧光原位杂交技术在前列腺癌诊断中的临床应用[J].中华腔镜泌尿外科杂志(电子版),2010,(01):64.
　SUN Qi-peng,PANG Jun,LI Liao-yuan,et al.Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the diagnosis of prostate cancer[J].,2010,(01):64.
[9]蒲小勇,陆敏华,高新,等.不同穿刺针数经直肠前列腺穿刺活检诊断前列腺癌的研究[J].中华腔镜泌尿外科杂志(电子版),2010,(05):347.
　PU Xiao-yong,LU Ming-hua,GAO Xin,et al.Comparative study of the different cores using transrectal prostate biopsy in diagnosis of prostate cancer[J].,2010,(01):347.
[10]刘小彭,高新,周祥福,等.耻骨后前列腺癌根治术联合内分泌治疗T3N1期前列腺癌[J].中华腔镜泌尿外科杂志(电子版),2010,(05):374.
　LIU Xiao-peng,GAO Xin,ZHOU Xiang-fu,et al.Radical prostatectomy combining with adjuvant hormone therapy for treatment of prostate cancer with pelvic lymph node metastasis[J].,2010,(01):374.
[11]许尔蛟,李凯,郑荣琴,等.射频消融联合内分泌治疗对中晚期前列腺癌治疗价值的初步研究[J].中华腔镜泌尿外科杂志(电子版),2012,(01):53.
　XU Er-jiao,LI Kai,ZHENG Rong-qin,et al.The preliminary study of radiofrequency ablation in combination with hormonal therapy for the treatment of intermediate and advanced prostate cancer[J].,2012,(01):53.

备注/Memo

备注/Memo:
基金项目：广州医学院博士启动项目（ 2010C37）
通讯作者：杨建安，Email：doctoryang99@163.com
更新日期/Last Update: 2014-02-25